Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
AdvisorShares Psychedelics ETF (PSIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PSIL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit -4.8% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Volume (30-day avg) - | Beta 0.69 | 52 Weeks Range 7.14 - 15.94 | Updated Date 06/29/2025 |
52 Weeks Range 7.14 - 15.94 | Updated Date 06/29/2025 |
Upturn AI SWOT
AdvisorShares Psychedelics ETF
ETF Overview
Overview
The AdvisorShares Psychedelics ETF (PSIL) is focused on companies involved in the research, development, cultivation, production, and distribution of psychedelic substances and related technologies.
Reputation and Reliability
AdvisorShares is known for its actively managed ETFs, often focusing on emerging or niche sectors. Their reliability is based on their adherence to regulatory standards and operational efficiency.
Management Expertise
The management team's expertise includes investment management and experience in identifying and managing investments in specialized sectors.
Investment Objective
Goal
To seek long-term capital appreciation by investing in companies expected to benefit from the growth of the psychedelics industry.
Investment Approach and Strategy
Strategy: The ETF is actively managed, selecting companies based on their potential within the psychedelics sector, not tracking a specific index.
Composition The ETF primarily holds stocks of companies involved in the psychedelics industry, including those in research, development, and production.
Market Position
Market Share: Market share varies as this is a niche market with evolving competition. Data is difficult to precisely quantify due to the emerging nature of the sector.
Total Net Assets (AUM): 3990000
Competitors
Key Competitors
- Defiance Next Gen Altered Experience ETF (PSY)
- The Conscious Fund ETF (MIND)
Competitive Landscape
The competitive landscape includes ETFs focused on the broader cannabis and psychedelics industries. PSIL benefits from being an early mover but faces competition from larger funds with greater resources. A disadvantage for PSIL is that it has a higher expense ratio when compared to PSY.
Financial Performance
Historical Performance: Historical performance depends on market conditions and sector developments. Data unavailable.
Benchmark Comparison: There is no direct benchmark index for psychedelics-focused ETFs, making benchmark comparisons challenging.
Expense Ratio: 0.0075
Liquidity
Average Trading Volume
The average trading volume for PSIL can be relatively low, which can impact trade execution.
Bid-Ask Spread
The bid-ask spread can be wider compared to more liquid ETFs, reflecting its niche focus.
Market Dynamics
Market Environment Factors
Regulatory changes, clinical trial results, and public perception are key market environment factors affecting PSIL.
Growth Trajectory
Growth depends on regulatory approvals, market acceptance, and the success of companies in the psychedelics industry. Recent trends include increased interest in mental health treatments.
Moat and Competitive Advantages
Competitive Edge
PSIL aims to be the premier ETF in the psychedelics space, offering targeted exposure to companies at the forefront of this emerging industry. Its active management allows for strategic allocation to companies with the most potential. It distinguishes itself by focusing specifically on psychedelics, avoiding dilution in broader sectors. However, the limited scale could make it difficult to compete with bigger firms.
Risk Analysis
Volatility
PSIL exhibits high volatility due to the nascent and speculative nature of the psychedelics industry.
Market Risk
Market risk includes regulatory hurdles, clinical trial failures, and changing public perception, all of which can significantly impact the value of underlying assets.
Investor Profile
Ideal Investor Profile
The ideal investor is one with a high-risk tolerance, seeking exposure to a high-growth, emerging sector, and comfortable with volatility and uncertainty.
Market Risk
PSIL is more suitable for active traders or investors with a long-term perspective and a specific interest in the psychedelics industry.
Summary
AdvisorShares Psychedelics ETF (PSIL) offers targeted exposure to the emerging psychedelics industry, marked by high growth potential and significant risks. This actively managed ETF seeks to capitalize on the burgeoning field of psychedelic medicines. Its success hinges on regulatory advancements, clinical trial results, and market adoption. PSIL's high-risk, high-reward profile makes it suitable for investors with a strong appetite for volatility and a long-term investment horizon. Investing in this ETF requires careful consideration of the sector's inherent uncertainties.
Peer Comparison
Sources and Disclaimers
Data Sources:
- AdvisorShares website
- ETF.com
- Yahoo Finance
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and after consulting with a financial advisor. Market share percentages are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AdvisorShares Psychedelics ETF
Exchange NYSE ARCA | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.